Issue link: http://www.e-digitaleditions.com/i/883179
industry news FDA approves first dyskinesia treatment for Parkinson's patients SILVER SPRINGS, MD—The FDA approved Gocovri (amanta- dine), the first treatment for dyskine- sia (involuntary and non-rhythmic muscle movements) in patients with Parkinson's disease. Delivered in extended-release capsules, Gocovri is manufactured by Adamas Pharma- ceuticals, Emeryville, CA. Cambrex to add analytical lab HIGH POINT, NC—Cambrex plans to add an 11,000-square-foot analytical lab to its facility here and hire 12 analytical development scien- tists to staff it. Cambrex, which man- ufactures small-molecule APIs for innovator and generic pharmaceuti- cal companies, acquired the High Point facility from PharmaCore in October 2016. Mylan, Otsuka to commercialize TB treatment in South Africa, India HERTFORDSHIRE, UK—Mylan Pharmaceuticals and Otsuka Pharma- ceutical, Tokyo, Japan, will commer- cialize Deltyba (delamanid), a treat- ment for pulmonary multidrug-resis- tant tuberculosis (MDR-TB), in South Africa and India. Together, the two countries accounted for more than 150,000 cases of MDR-TB in 2015, according to estimates from the World Health Organization. Teva to sell women's health business JERUSALEM, Israel—Teva Phar- maceutical agreed to sell the remain- der of its specialty global women's health business to CVC Capital Partners of Luxembourg and Foundation Consumer Healthcare, Pittsburgh, PA. CVC will take over Teva's contraceptive, fertility, and menopause products. Foundation will acquire its levonorgestrel-based emer- gency contraceptive tablets portfolio. 8 October 2017 Tablets & Capsules